Hammarbäck S, Bäckström T
Department of Obstetrics & Gynecology, University of Umeå, Sweden.
Acta Obstet Gynecol Scand. 1988;67(2):159-66. doi: 10.3109/00016348809004191.
A treatment with the GnRH-agonist, buserelin, was given intranasally in a dosage of 400 micrograms once daily, to induce anovulation in 26 women with premenstrual tension syndrome; 23 patients completed the study course. The design was double-blind and cross-over. Daily symptom ratings were made for two pretreatment, diagnostic cycles and continued for up to six cycles or 6 months. The rating scale used was an earlier described visual analogue scale. Blood samples for estradiol and progesterone radio-immunoassay were taken once weekly throughout the study. Results show beneficial effects of both placebo and GnRH-agonist, compared with the pretreatment situation. The GnRH-agonist was, however, significantly better than placebo. At the end of the treatment periods the patients while still taking placebo, still showed cyclical symptom changes, whereas during the GnRH-agonist treatment the cyclical changes had disappeared. The results indicate that a factor from the corpus luteum must be involved in the etiology of cyclical mood changes. The results also show that inhibition of ovulation by mean of GnRH-agonists is one possible way to treat premenstrual tension syndrome.
对26名患有经前紧张综合征的女性，采用鼻内给予促性腺激素释放激素（GnRH）激动剂布舍瑞林的治疗方法，剂量为每日400微克，以诱导无排卵；23名患者完成了研究疗程。研究设计为双盲交叉试验。在两个预处理诊断周期内每日进行症状评分，并持续进行多达六个周期或6个月。所使用的评分量表是先前描述的视觉模拟量表。在整个研究过程中，每周采集一次血样用于雌二醇和孕酮的放射免疫测定。结果显示，与预处理情况相比，安慰剂和GnRH激动剂均有有益效果。然而，GnRH激动剂明显优于安慰剂。在治疗期结束时，患者在仍服用安慰剂时，仍表现出周期性症状变化，而在GnRH激动剂治疗期间，周期性变化消失。结果表明，黄体产生的一种因子必定参与了周期性情绪变化的病因。结果还表明，通过GnRH激动剂抑制排卵是治疗经前紧张综合征的一种可能方法。
